Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2005-09-16
2010-06-15
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C530S351000, C514S012200, C435S069500, C435S320100, C536S023500
Reexamination Certificate
active
07736638
ABSTRACT:
Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15Rα) and TNFα-mediated apoptosis.Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15Rα expression is associated to the disease progression.
REFERENCES:
patent: 5894018 (1999-04-01), Davia et al.
patent: 6013480 (2000-01-01), Grabstein et al.
patent: 6344192 (2002-02-01), Grooten et al.
patent: 0927254 (2005-06-01), None
patent: WO 95/27722 (1995-10-01), None
patent: WO9604306 (1996-02-01), None
patent: WO0002582 (2000-01-01), None
patent: WO01/02003 (2001-01-01), None
patent: WO2005/085282 (2005-09-01), None
Lazar et al, Mol. Cell. Biol., 1988, vol. 8, pp. 1247-1252.
Wells, 1990, Biochemistry 29:8509-8517.
Silva et al, Inflammatory bowel disease, Mar. 2005, vol. 11, No. 3, pp. 219-230.
Crystal, R. Science, 1995, vol. 270, pp. 404-410.
Verma et al. Nature, 1997, vol. 389, p. 239-242.
Ross et al, Human Gene Therapy, 1996, vol. 7, pp. 1781-1790.
Rubanyi, Biol. Aspects Med. 2001, vol. 22, pp. 113-142.
I. B. McInnes, Book Series: Ernst Schering Foundation Symposium Proceedings, Publisher: Springer Berlin Heidelberg, 2006, vol. 56, pp. 29-44.
Bernard J., et al., “Identification of an Interleukin-15 Alpha Receptor-Binding Site on Human Interleukin-15”, Journal of Biological Chemistry, American Society of Biochemical Biologists, vol. 279, No. 23, pp. 24313-24322 (Jun. 4, 2004).
Fehniger T.A. et al., “Interleukin 15: Biology and Relevance to Human Disease”, Blood, W.B. Saunders Company, vol. 97, No. 1, pp. 14-32 (Jan. 1, 2001).
Brewer JM et al., “Aluminum Hydroxide Adjuvant Initiates Strong Antigen-Specific Th2 Responses in the Absence of IL-4- or IL-13-mediated Signaling”, J. Immunol, vol. 163:6448-6454 (1999).
Gonzalez, S. et al., “P64k Meningococcal Protein as Immunological Carrier for Weak Immunogens”, Scan J. Immunol. vol. 52, p. 113-116 (2000).
Schwartz RH and Muller DL, Immunological Tolerance. In Fundamental Immunology, 5th Ed. W.E. Paul (Ed)., Lippincott, Williams, and Wilkins p. 901-934 (2003).
Al-Mughales J. et al., “The Chemoattractant Activity of Rheumatoid Synovial Fluid for Human Lymphocytes is Due to Multiple Cytokines”, Clin. Exp. Immunol. vol. 106: 230-236 (1996).
Obermeier F. et al., “IL-15 Protects Intestinal Epithelial Cells”, Eur. J. Immunol, vol. 36: 2691-2699 (2006).
Kukita T. et al., “Autocrine and/or Paracrine Growth of Adult T-Cell Leukaemia Tumour Cells by Interleukin 15”, Br. J. Haematol., vol. 119:467-474 (2002).
Acosta Osvaldo Reyes
Aguero Celia Aurora Arrieta
Perea Rodriguez Silvio Ernesto
Perez Haydee Geronimo
Rico Ania Cabrales
Bunner Bridget E
Centro de Ingenieria Genetica y Biotecnologia
Hamud Fozia M
Hoffmann & Baron , LLP
LandOfFree
Interleukin-15 antagonist peptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-15 antagonist peptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-15 antagonist peptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4166804